Rocatinlimab + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prurigo Nodularis
Conditions
Prurigo Nodularis
Trial Timeline
Jul 18, 2024 → Jan 17, 2027
NCT ID
NCT06527404About Rocatinlimab + Placebo
Rocatinlimab + Placebo is a phase 3 stage product being developed by Amgen for Prurigo Nodularis. The current trial status is active. This product is registered under clinical trial identifier NCT06527404. Target conditions include Prurigo Nodularis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06527404 | Phase 3 | Active |
| NCT06376045 | Phase 2 | Active |
| NCT05899816 | Phase 3 | Completed |
| NCT05704738 | Phase 3 | Completed |
| NCT05398445 | Phase 3 | Completed |
Competing Products
20 competing products in Prurigo Nodularis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vixarelimab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Upadacitinib | AbbVie | Approved | 85 |
| Pimecrolimus + Hydrocortisone + Pimecrolimus | Novartis | Phase 2 | 52 |
| Abrocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab SAR231893 (REGN668) | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Phase 3 | 76 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Ruxolitinib Cream 1.5% | Incyte | Phase 1 | 30 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| INCB054707 + Placebo | Incyte | Phase 2 | 49 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| CDX-0159 + Normal saline | Celldex Therapeutics | Phase 1 | 28 |
| barzolvolimab | Celldex Therapeutics | Phase 2 | 47 |
| nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 60 |
| Nalbuphine ER Tablets + Placebo Tablets | Trevi Therapeutics | Phase 2/3 | 60 |
| serlopitant + Placebo | Vyne Therapeutics | Phase 2 | 44 |